RadNet (RDNT) has agreed to acquire iCad (ICAD) in an all-stock deal valued at roughly $103 million, the companies said late Tuesday.
Shares of iCad jumped more than 72% in recent after-hours activity, while those of RadNet were down 2%.
As part of the agreement, iCad shareholders will receive 0.0677 shares of RadNet common stock for each iCad share they own, valuing it at $3.61 per share, a 98% premium based on the closing prices Monday.
The acquisition is expected to merge advanced artificial intelligence technologies from both companies to strengthen early breast cancer detection and streamline diagnostic workflows, the companies said.
The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3, pending iCad stockholder approval and customary closing conditions, according to a joint statement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。